Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy.
Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy.
复制标题
黄芪上调 Cosmc 表达并逆转 IgA 肾病中的 IgA 糖基化异常。
DOI：
10.1186/1472-6882-14-195
复制
发表时间：
2014-06-18
影响因子：
--
通讯作者：
Qin W
中科院分区：
文献类型：
--
作者：
Ji L;Chen X;Zhong X;Li Z;Yang L;Fan J;Tang W;Qin W
核心I β3- gal - t特异性分子伴侣（Cosmc）表达降低诱导IgA1异常糖基化是IgA肾病（IgAN）的主要特征。本研究旨在探讨黄芪对IgAN患者外周血B淋巴细胞Cosmc表达及IgA o -糖基化的影响。采用脂多糖（LPS）和黄芪注射液（AMI）分别对21例IgAN患者和10例正常人外周血B淋巴细胞进行分离培养。采用实时RT-PCR和Western blot检测Cosmc mRNA和蛋白的表达水平。采用酶联免疫吸附法（ELISA）和VV凝集素结合法检测IgA1和糖基化水平。IgAN患者的Cosmc mRNA表达和IgA1 o -糖基化水平在基线时显著低于正常对照。LPS处理可明显抑制IgAN患者外周B淋巴细胞Cosmc表达，增加IgA1分泌，导致IgA1异常糖基化水平显著升高。AMI的加入可显著上调Cosmc的表达，降低IgA1的分泌，逆转糖基化水平，并呈剂量相关。AMI可上调外周B淋巴细胞Cosmc表达，逆转IgA1异常o糖基化水平，这可能是AMI治疗IgAN的潜在机制。TCTR20140515001（注册日期：2014-05-15）
Decreased Core I β3-Gal-T-specific molecular chaperone (Cosmc) expression induced IgA1 aberrant glycosylation is the main characteristic of IgA nephropathy (IgAN). This study tried to elucidate the effect of Astragalus membranaceus on Cosmc expression and IgA O-glycosylation of peripheral B lymphocytes in IgAN patients. Peripheral B lymphocytes of 21 IgAN patients and 10 normal controls were isolated and cultured with or without lipopolysaccharide (LPS) and Astragalus membranaceus injection (AMI). Cosmc mRNA and protein expression levels were measured by real-time RT-PCR and Western blot. IgA1 and glycosylation level were determined by enzyme-linked immunosorbent assay (ELISA) and VV lectin-binding method. Cosmc mRNA expression and IgA1 O-glycosylation level in IgAN patients was significantly lower than normal controls at baseline. Treatment of LPS could obviously inhibit Cosmc expression and increase the IgA1 secretion in peripheral B lymphocytes of IgAN patients, which resulted in a significantly increase in IgA1 aberrant glycosylation level. Addition of AMI could remarkably up regulated Cosmc expression, decrease IgA1 secretion, and reverse glycosylation level in a dose related manner. AMI can up-regulate Cosmc expression of peripheral B lymphocytes and reverse IgA1 aberrant O-glycosylation level, which might be the underlying mechanism of AMI therapy in treating IgAN. TCTR20140515001 (Registration Date: 2014-05-15)
登录
查看更多内容
影响因子：
5.1
作者：
Zuo, Chuan;Xie, Xi-sheng;Fan, Jun-ming
通讯作者：
Fan, Jun-ming
影响因子：
6.1
作者：
Qin, Wei;Zhong, Xiang;Ma, Xing Yi
通讯作者：
Ma, Xing Yi
影响因子：
19.6
作者：
通讯作者：
--
影响因子：
2
作者：
Xie, Linshen;Tan, Chunyu;Qin, Wei
通讯作者：
Qin, Wei
影响因子：
5.4
作者：
Li, Mingxin;Wang, Weixin;Lin, Shanyan
通讯作者：
Lin, Shanyan